CST, 50661S, VEGF-A (E9X8Q) Rabbit Monoclonal Antibody

Monoclonal Antibody for studying VEGF. Validated for Western Blotting,Immunoprecipitation. Available in 2 sizes. Highly specific and rigorously validated in-house, VEGF-A (E9X8Q) Rabbit Monoclonal Antibody (CST #50661) is ready to ship. Product Usage Information Western Blotting: 1:1000 Immunoprecipitation: 1:200 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting, Immunoprecipitation Specificity / Sensitivity VEGF-A (E9X8Q) Rabbit Monoclonal Antibody recognizes endogenous levels of total VEGF-A protein. Species Reactivity: Human Source / Purification Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the amino terminus of human VEGF-A protein. Background Vascular endothelial growth factor-A (VEGF-A; formerly VEGF) belongs to the VEGF/PDGF family of growth factors that play a critical role in promoting vascular development. VEGF-A is primarily known for its function in promoting angiogenesis, the process by which new blood vessels are sprouted from pre-existing blood vessels. VEGF-A has eight isoforms, derived from differentially spliced mRNA variants encoded by the gene (1). All isoforms contain a conserved receptor binding domain, but differ in their C-terminal domains that regulate binding to components in the extracellular matrix. VEGF-A is secreted by multiple cell types, including fibroblasts, macrophages, and some tumor cells (1). Binding of VEGF-A to its cognate receptors (VEGFR2 and to a lesser extent VEGFR1) on the endothelial cell surface activates the receptor and initiates downstream signaling, resulting in endothelial cell proliferation, survival, migration, and changes to vascular permeability, all crucial processes for angiogenesis (3). Tumor cells have been shown to respond to hypoxia by increasing mRNA expression. Increased secretion of VEGF-A in the tumor microenvironment stimulates angiogenesis to further promote tumor progression (4). In addition to promoting tumor angiogenesis, VEGF-A has also been shown to play an important role in normal tissue development, tissue regeneration, tumor cell proliferation, neovascular eye diseases, and cancer immunity (2,5). For this reason, targeting angiogenesis via the VEGF-A pathway has been a major focus in cancer therapeutics research. Alternate Names MVCD1; Vascular endothelial growth factor A; Vascular endothelial growth factor A, long form; vascular endothelial growth factor A121; vascular endothelial growth factor A165; Vascular permeability factor; VEGF; VEGF-A; VEGFA; VPF Specification REACTIVITY: H SENSITIVITY: Endogenous MW (kDa): 16, 20, 23, 26 Source/Isotype: Rabbit IgG